Board of Directors

Larry Papasan

Mr. Papasan serves as the Co-Chairman and Director of the Company. From July 1991 until his retirement in May 2002, Mr. Papasan served as President of Smith & Nephew Orthopedics. He has been a Director and Chairman of the Board of Directors of BioMimetic Therapeutics, Inc. (NasdaqGM:BMTI) , Mr. Papasan has also served as a member of the Board of Directors of Reaves Utility Income Fund (NasdaqCM:UTG), a closed-end management investment company, since February 2003 and of Triumph Bancshares, Inc. (a bank holding company) since April 2005.

Steve Gorlin

Steve Gorlin is the Co-founder of Debride Inc., the first company acquired by Medovex. Over the past 40 years, Mr. Gorlin has founded several biotechnology and pharmaceutical companies, including HycorBiomedical, Inc. (acquired by Agilent), Theragenics Corporation (NYSE: TGX) , CytRx Corporation (NASDAQ: CYTR), Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc. (NASDAQ: ENMD), MRI Interventions (MRIC), DARA BioSciences, Inc. (NASDAQ: DARA), MiMedx (NASDAQ: MDXG), and Medivation, Inc. (NASDAQ: MDVN). Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board. He presently serves on the board of driectors of the Andrews Institute. Mr. Gorlin founded a number of non-medical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc. (sold to Network Associates), and NTC China. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. Presently, he serves as Executive Chairman of DemeRx, Inc., Conkwest, Inc., and on the Board of NTC China, Inc.

Major General C.A. "Lou" Hennies

Lou Hennies, serves as Director of the Company and served his country in uniform for 41 years, he served a total of 37 months in combat in Republic of Vietnam, selected for Brigadier General in 1986, rose to Major General before retiring. His awards and decorations include the Army Distinguished Medal with Oak Leaf Cluster, the Silver Star, the Legion of Merit with Oak Leaf Cluster, the Distinguished Flying Cross, the Soldiers Medal, the Bronze Star with “V” device and 5 Oak Leaf Clusters, the Purple Heart, the Air Medal with “V” (2) and numeral 29, and the Alabama Distinguished Medal with Oak Leaf Cluster. He is also a recipient of numerous foreign decorations from Republic of Vietnam and the Republic of Korea.

James R. Andrews, M.D.

Dr. Andrews serves as a director of the company and is internationally known and recognized throughout the world for his scientific and clinical research contributions in knee, shoulder and elbow injuries, and his skill as an orthopedic surgeon. Dr. Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida. In addition, he is a founding member of the American Sports Medicine Institute (ASMI). Involved in education and research in sports medicine and orthopedic surgery, he has made major presentations on every continent, and has authored numerous scientific articles and books.

Randal R. Betz, M.D.

Dr. Betz, serves as Director of the company and currently holds hospital positions as Chief of Staff at Shriners Hospitals for Children and Medical Director of Shriners’ Spinal Cord Injury Unit. Additionally, Dr. Betz is currently on staff at Temple University Children’s Medical Center and is a Professor of Orthopedic Surgery at Temple University School of Medicine. Many national and international professional societies count Dr. Betz as a member. In addition to active hospital practice in pediatric spinal surgery, research is an important area of Dr. Betz’s career. He has contributed 31 chapters to medical books and written 153 peer-reviewed or invited articles.

Scott M. W. Haufe, M.D.

Dr. Haufe is co-founder of MEDOVEX and a Director of the Company. Dr. Haufe is a board certified physician in the fields of Anesthesiology, Pain Medicine and Hospice /Palliative Medicine. He began his career in the field of Anesthesiology where he served as Chief of Anesthesiology and Pain Management with St. Lucie Anesthesia Associates while continuing his passion for research.

Jarrett Gorlin

Mr. Gorlin serves as the Chief Executive Officer and a Director of the Company. He previously co-founded and served as President of Judicial Correction Services, Inc. which was named three consecutive years in a row as one of America’s fastest growing companies by Inc. Magazine. He served as President of Judicial Correction Services until successfully negotiating its sale to Correctional Healthcare Companies in 2011. He remained with Correctional Healthcare as its President until 2013.

John C. Thomas, Jr.

John Thomas currently serves as the CFO for Cormatrix Cardiovascular, Inc., a privately held medical device company which he joined in 2001. Over the past 24 years, Mr. Thomas has served as the CFO of numerous startup companies and managed their financing activities from the initial financing up to their initial public offering. Some of these companies are still private and some have become public entities. The companies in the health care industry that have gone public while Mr. Thomas was the CFO include CytRx Corporation (1986 – 1990), CytRx Biopool (1988 – 1991), Medicis Pharmaceutical Corporation (1988 –1991), EntreMed, Inc. (1991 – 1997), DARA BioSciences, Inc. (1998 – 2009) and, MiMedx, Inc. (2006 – 2009). He has also been the CFO of Surgi-Vision, Inc., a private research company involved in MRI technology (1998 – 2010).Mr. Thomas has also been the CFO of Motion Reality, Inc., a privately-held company with proprietary software that captures and analyzes motion data since 1991. Mr. Thomas is a certified public accountant and is the Chairman of the Finance Committee and a Trustee at The Walker School, a private pre-K through 12th grade school in Marietta, Georgia.

Ron Lawson's 35 plus years of experience in the orthopedic industry include the role as Senior Vice President of Worldwide Sales and Customer Service for Pfizer's Orthopedic Division, Howmedica (1996). In 1998, he became part of the Stryker Corporation with Stryker's acquisition of Howmedica. At Stryker, he served as Senior Vice President of Sales, Marketing and Product Development. Mr. Lawson also played a critical and insightful role in the successful integration of the two companies. In 2000, he was asked to lead the revitalization of Stryker's European business as President, EMEA. He shortly thereafter assumed the role of leadership for all of Stryker's International distribution businesses and was promoted to Group President, International in 2001.

In 2005, Stryker assigned global responsibility of their orthopedic division to Mr. Lawson making him Group President for International and Global Orthopedics. He then focused on strengthening the Stryker Orthopedic business worldwide. Ron retired from Stryker at the end of 2007.

Ron Lawson is currently a member of the Lawson Group where he provides strategic consulting services specializing in orthopedic medical technology. He previously served as Chairman of the Board of IMDS, Corporation. He also served as a member of the Health Care Advisory Board of Arsenal Capital Partners. He presently serves as a Director of Plasmology 4, Corporation as well as a Director of DJO Global, a Blackstone company.

Dr. Mogford serves as the Vice Chancellor for Research for the Texas A&M University System and provides research and development leadership to the System’s eleven universities and seven state agencies encompassing 30,000 faculty and staff, >135,000 students, a budget of more than $4 billion and research expenditures of more than $945 million annually. As the leader of the A&M System Office of Research, he develops strategic partnerships with external agencies, foundations, academic institutions, and commercial corporations to enhance the system’s mission of research, teaching, service and economic development for the state of Texas.

Prior to joining the Texas A&M University System in 2011, Dr. Mogford served as a program manager and then Deputy Director of the Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense. As DSO Deputy Director, he provided strategic planning and implementation of ≈$400M/year in R&D in the physical, biomedical and material sciences. He provided leadership to 20 Program Managers in the development and management of office investments ranging from the fundamental sciences to commercial transition efforts for both defense and non-defense applications. Dr. Mogford led expansion of formal working relationship between DARPA and the FDA to improve the ability of each organization to meet mission goals, which were highlighted as a DARPA-FDA-NIH partnership by the White House. He is the recipient of the Secretary of Defense Medal for Outstanding Public Service.

His DARPA programs included scar-free regeneration of wounds, metabolic control strategies for survival of severe blood loss, biomarker-responsive biomaterials for drug delivery, stem cell-based bioreactor production of universal donor red blood cells, computational design of novel proteins, and active hemostatic biomaterials for treatment internal and external wounds. He has authored or co-authored 29 peer-reviewed publications.

Dr. Mogford obtained his bachelor’s degree in Zoology from Texas A&M University and doctorate in Medical Physiology from the Texas A&M University Health Science Center, College Station, Texas. His research in vascular physiology continued at the University of Chicago as a Postdoctoral fellow from 1997-98. Dr. Mogford transitioned his research focus to the field of wound healing at Northwestern University, both as a Research Associate and also as a Research Assistant Professor from 1998-2003. He then served as a Life Sciences Consultant to DARPA on the Revolutionizing Prosthetics program from 2003-2005.

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.